1. Effect of beraprost sodium on renal function and p38MAPK signaling pathway in rats with diabetic nephropathy.
- Author
-
Liangxiao Xie, Jiajia Dong, Jinzhi Wu, Changshun Wei, Kezhen Xu, Pengbin Lai, and Xiaoyun Zha
- Subjects
- *
DIABETIC nephropathies , *KIDNEY physiology , *HDL cholesterol , *LDL cholesterol , *CELLULAR signal transduction , *WESTERN immunoblotting - Abstract
Purpose: To investigate the effect of beraprost sodium (BPS) on renal function and P38MAPK pathway in diabetic nephropathy (DN) rats. Methods: Sprague Dawley (SD) rats (n = 30) were randomly divided into three groups, viz, normal control (NC), diabetic nephropathy (DN) and beraprost sodium (BPS). Creatinine (Cr), blood urea nitrogen (BUN) and fasting blood glucose (FBG), were determined by Hitachi 7020 automatic biochemical analyzer, while low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and total cholesterol (TC) were measured by Olympus 400 automatic biochemical analyzer. Western blot analysis was performed to examine protein expression. Interleukin-6 (IL-6), hs-CRP, and TNF-a levels were evaluated using enzyme linked immunosorbent assay (ELISA). Results: After 8 weeks of treatment, renal function indices (urine output, KW/BW, UAlb/24 h, Cr and BUN), blood lipid indices (FBG, LDL-C, TG and TC) and inflammatory factors levels (IL-6, hs-CRP and TNF-a) in DN group were higher than NC group (p < 0.05). In BPS group, renal function and blood lipid indices and inflammatory factor levels decreased when compared to DN group (p < 0.05). Furthermore, BPS inhibited the protein expression of p-P38MAPK, TGF-ß1 and COX-2. Conclusion: Beraprost sodium improves renal function in DN rats by inhibiting P38MAPK signaling pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF